ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Imexpharm (IMP.VN)
Imexpharm stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Ho Chi Minh Stock Exchange · Vietnam
₫35,750▲ +1.56%
Prices as of Oct 27, 2026 · VND
Chance of rising in 1 month
51%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Imexpharm in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Imexpharm
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Imexpharm a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₫34,145 and ₫37,620; in 9 out of 10, between ₫31,334 and ₫40,995. Estimated annual volatility is 28%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₫5.5T
- Market cap (USD)
- $212M
- P/E ratio
- 85.6
- 52-week high
- ₫57,000
- 52-week low
- ₫32,650
- Revenue (12 months)
- ₫2.3T
- Gross margin
- 48.0%
- Operating margin
- 20.8%
- Net margin
- 15.5%
- Beta
- 0.43
What this means
ATLAS does not publish a fair value for IMP.VN right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks IMP.VN has traded between ₫32,650 and ₫57,000. Today it is 37.3% below that high and 9% above its low.
On the business: net margin is 15.5%; it trades at 85.6 times earnings.
Its beta is 0.43: it tends to move less than the market.
About the company
Imexpharm Corporation operates as a pharmaceutical company in Vietnam.
Want to see everything about Imexpharm?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Imexpharm do?
Imexpharm Corporation operates as a pharmaceutical company in Vietnam.
What is the chance IMP.VN goes up next month?
51%: close to a coin flip. In half of the simulated outcomes, IMP.VN ends the month between ₫34,145 and ₫37,620.
How big is Imexpharm and what is its P/E ratio?
Imexpharm's market capitalization is ₫5.5T. Its price-to-earnings (P/E) ratio is 85.6: you pay ₫85.6 for each ₫1.00 of yearly earnings.
How volatile is IMP.VN?
ATLAS estimates annual volatility at 28%. In a typical month, half of the outcomes end between ₫34,145 and ₫37,620.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer